Navidea Biopharmaceuticals (NAVB) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock NAVB vs. SMFL, TRVN, SCPS, EVLO, GNCAQ, GNCA, STAB, AMPE, CMRA, and SYRSShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Smart for Life (SMFL), Trevena (TRVN), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Its Competitors Smart for Life Trevena Scopus BioPharma Evelo Biosciences Genocea Biosciences Genocea Biosciences Statera Biopharma Ampio Pharmaceuticals Comera Life Sciences Syros Pharmaceuticals Smart for Life (NASDAQ:SMFL) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Which has more volatility & risk, SMFL or NAVB? Smart for Life has a beta of 16.69, meaning that its share price is 1,569% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Is SMFL or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Smart for LifeN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Which has better valuation and earnings, SMFL or NAVB? Navidea Biopharmaceuticals has lower revenue, but higher earnings than Smart for Life. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmart for Life$11.11M0.00-$22.68MN/AN/ANavidea Biopharmaceuticals$8.13K0.00-$15.18MN/AN/A Do institutionals & insiders have more ownership in SMFL or NAVB? 28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to SMFL or NAVB? In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Smart for Life Neutral Navidea Biopharmaceuticals Neutral SummarySmart for Life beats Navidea Biopharmaceuticals on 3 of the 5 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$10K$35.02M$6.10B$22.13BDividend YieldN/AN/A5.64%3.55%P/E RatioN/AN/A85.6629.95Price / SalesN/A26.46527.8370.63Price / CashN/AN/A26.3018.33Price / BookN/AN/A12.904.65Net Income-$15.18M-$21.09M$3.30B$1.01B Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010High Trading VolumeSMFLSmart for LifeN/A$0.01-16.7%N/A-85.0%$35K$11.11M0.00110Gap DownTRVNTrevena2.0674 of 5 stars$0.02+25.0%$5.00+33,233.3%-99.7%$14K$443K0.0040Gap UpSCPSScopus BioPharmaN/A$0.00flatN/A+0.0%$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Gap DownGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070STABStatera BiopharmaN/A$0.00flatN/AN/A$5KN/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020CMRAComera Life SciencesN/AN/AN/AN/A$3K$1.00M0.002News CoverageSYRSSyros Pharmaceuticals3.8404 of 5 stars$0.00flat$1.00+999,900.0%-99.7%$3K$386K0.00120Gap Up Related Companies and Tools Related Companies Smart for Life Competitors Trevena Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Comera Life Sciences Competitors Syros Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredThe Dollar’s Crashing—What Are You Doing About It?The U.S. dollar is down 10.8%—its steepest drop since 1973. As global confidence in the dollar fades, centr...Lear Capital | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
